

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA: Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A consultee organisation raised 2 potential equality issues:

1. A potential to disadvantage patients over the age of 50-55 years because these were excluded from the relevant clinical trials.
2. A perceived inequality for patients who have been treated with glatiramer in the access to fingolimod, and that such a situation should be avoided.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

1. Guidance will only be issued in line with marketing authorisation, and it is not expected to be restricted to people below 50—55 years of age
2. This is not an issue relevant for the Committee, because the wording of NICE's recommendation for fingolimod was (and needs to be) based on the marketing authorisation for fingolimod, and this would be the same in this appraisal.

3. Has any change to the draft scope been agreed to highlight potential

equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None have been identified.

Approved by Associate Director (name): Elisabeth George

Date: 16 05 13